ClinicalTrials.gg
RecruitingNCT07309107DEEPAMYUpdated Jun 25, 2026

Deep Learning on Amyloid Positons Emission Tomography

An observational study in Alzheimer Disease, sponsored by Central Hospital, Nancy, France. Recruiting at 3 sites in France. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-06-25.

Sponsored by Central Hospital, Nancy, France · Observational

How we know

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Retrospective
Enrollment
40
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Alzheimer Disease by Central Hospital, Nancy, France — 9 open to participants now, 9 under way, none of them phase 3. Alzheimer Disease · Central Hospital, Nancy, France.

Started
2026
with 1 other
Observational
8 of 17
5 open now
Registered
16th of 17
by date

Among the 17 studies in Alzheimer Disease by Central Hospital, Nancy, France, this one is one of 2 that started in 2026, is one of 8 observational ones, and was the 16th registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

9 of the 17 studies in Alzheimer Disease by Central Hospital, Nancy, France are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

Who these studies take

Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Alzheimer Disease by Central Hospital, Nancy, France, or all of them as a file.
02

Study summary

Reducing injected dose and/or acquisition time in amyloid PET imaging would improve comfort, radiation safety and cost-effectiveness in diagnosis and follow-up of patients. This study evaluates the impact of a deep learning-based noise reduction algorithm on visual analysis and Centiloid quantification when simulating reduced injected doses of [18F]flutemetamol.

03

Conditions studied

  • Alzheimer Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Sampling method
Probability sample

Study population

Patients with objective cognitive impairment, referred to our department for a cerebral [¹⁸F]flutemetamol positron emission tomography scan between January 1, 2023 and July 1, 2025, will be included

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with objective cognitive impairment,
  • Referred to our department for a cerebral [¹⁸F]flutemetamol positron emission tomography scan between January 1, 2023 and July 1, 2025,

Exclusion criteria

Exclusion Criteria:

  • Patient have objected to the use of their data.
05

Study design

Observational model
Other
Time perspective
Retrospective
Enrollment
40 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Evaluate the impact of a deep-learning noise reduction algorithm on visual analysis and centiloid quantification when simulating reduced injected doses of 18F-flutemetamol.

    Visual analysis of the cerebral \[¹⁸F\]flutemetamol PET images will be performed by two nuclear medicine specialists in a blinded manner, with a third reader acting as an arbitrator in case of disagreement, according to routine diagnostic criteria.

    Time frame: Day one

07

Study locations

3 of 3 sites recruiting
  • CHRU NANCY Brabois, nuclear medicine department
    Vandœuvre-lès-Nancy, 54511, France
    Recruiting
  • Nancy's hospital
    Vandœuvre-lès-Nancy, 54511, France
    Recruiting
    • Antoine Verger, PhD · Contact
  • Nuclear medicine department CHRU de NANCY Brabois
    Vandœuvre-lès-Nancy, 54511, France
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2026 (actual). Primary completion is estimated for Nov 2026, 6 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 24, 2025
First posted
Dec 30, 2025
StartActual
May 6, 2026
Primary completionEst.
Nov 20, 2026
CompletionEst.
Jan 30, 2027
Last update
Jun 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07309107
Responsible party
Antoine VERGER (Principal Investigator, Central Hospital, Nancy, France) — Principal investigator
First posted
Dec 30, 2025
Start date
May 6, 2026
Primary completion
Nov 20, 2026 (estimated)
Completion
Jan 30, 2027 (estimated)
Last update
Jun 25, 2026

Study contacts

Antoine VERGER, MD,PhD
Contact
a.verger@chru-nancy.fr
0383155567 ext. +33
Veronique Roch, MSc
Contact
v.roch@chru-nancy.fr
0383154276
Principal Investigator
principal investigator · CHRU of NANCY

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion